FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216304313> ?p ?o ?g. }

• W3216304313 abstract "Elevated LDL-C is a major risk factor for atherosclerotic cardiovascular disease, the leading cause of death worldwide. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has pronounced effects on LDL-C levels via its modulation of hepatic LDL receptors (LDLR), the main pathway for cholesterol removal from the circulation. The epidermal growth factor precursor homology domain A (EGF-A) of the LDLR serves as a primary contact with PCSK9 via a flat interface, presenting a challenge for identifying small molecule PCSK9-LDLR disruptors. We employed an affinity-based screen of 10 13 in vitro -translated macrocyclic peptides to identify high affinity PCSK9 ligands that utilize a novel, induced-fit pocket and partially disrupt the PCSK9-LDLR interaction (Hit 1 - PCSK9-LDLR FRET, IC 50 2 nM, A max 41%). Structure-based design led to 13 PCSK9i , a molecule with enhanced in vitro function (PCSK9-LDLR FRET, IC 50 2 nM, A max 78%) and pharmacokinetic properties suitable for in vivo evaluation. To determine if 13 PCSK9i ’s functional activity in vitro would translate in vivo , C57BL/6 mice were dosed with vehicle or 13 PCSK9i via subcutaneous injection twice-daily for 3 days, and blood and liver were collected for the measurement of plasma total cholesterol (TC) and hepatic LDLR density. A PCSK9 antibody was included as a positive control. As illustrated in the figure, 13 PCSK9i increased hepatic LDLR density in a dose-dependent manner. Despite being 1/100 th its size, 13 PCSK9i (MW = 1.65 kDa) increased hepatic LDLR density on par with a PCSK9 antibody (MW = 144 kDa). Plasma TC levels were significantly reduced versus vehicle in all 13 PCSK9i dose groups, with similar reductions noted in the 13 PCSK9i 30 mg/kg and PCSK9 antibody groups (44% and 48%, respectively). In summary, 13 PCSK9i breaks new ground with its previously undescribed allosteric mechanism and, in turn, as the smallest molecule identified to date with in vivo PCSK9-LDLR disruptor function." @default.
• W3216304313 created "2021-12-06" @default.
• W3216304313 creator A5001532920 @default.
• W3216304313 creator A5002820625 @default.
• W3216304313 creator A5004583777 @default.
• W3216304313 creator A5007600129 @default.
• W3216304313 creator A5008418885 @default.
• W3216304313 creator A5010481269 @default.
• W3216304313 creator A5012171078 @default.
• W3216304313 creator A5012408085 @default.
• W3216304313 creator A5013353605 @default.
• W3216304313 creator A5016086086 @default.
• W3216304313 creator A5016539643 @default.
• W3216304313 creator A5027511093 @default.
• W3216304313 creator A5029046324 @default.
• W3216304313 creator A5031625792 @default.
• W3216304313 creator A5032741097 @default.
• W3216304313 creator A5033285773 @default.
• W3216304313 creator A5034258667 @default.
• W3216304313 creator A5047423654 @default.
• W3216304313 creator A5050799087 @default.
• W3216304313 creator A5051049396 @default.
• W3216304313 creator A5053977995 @default.
• W3216304313 creator A5056280633 @default.
• W3216304313 creator A5061178911 @default.
• W3216304313 creator A5062829074 @default.
• W3216304313 creator A5062980285 @default.
• W3216304313 creator A5064342343 @default.
• W3216304313 creator A5065511569 @default.
• W3216304313 creator A5070756624 @default.
• W3216304313 creator A5072750068 @default.
• W3216304313 creator A5073439100 @default.
• W3216304313 creator A5077618800 @default.
• W3216304313 creator A5077916667 @default.
• W3216304313 creator A5079259624 @default.
• W3216304313 creator A5083553613 @default.
• W3216304313 date "2021-11-16" @default.
• W3216304313 modified "2023-09-28" @default.
• W3216304313 title "Abstract 10516: Identification of a PCSK9-LDLR Disruptor Macrocycle with <i>in vivo</i> Function" @default.
• W3216304313 doi "https://doi.org/10.1161/circ.144.suppl_1.10516" @default.
• W3216304313 hasPublicationYear "2021" @default.
• W3216304313 type Work @default.
• W3216304313 sameAs 3216304313 @default.
• W3216304313 citedByCount "0" @default.
• W3216304313 crossrefType "journal-article" @default.
• W3216304313 hasAuthorship W3216304313A5001532920 @default.
• W3216304313 hasAuthorship W3216304313A5002820625 @default.
• W3216304313 hasAuthorship W3216304313A5004583777 @default.
• W3216304313 hasAuthorship W3216304313A5007600129 @default.
• W3216304313 hasAuthorship W3216304313A5008418885 @default.
• W3216304313 hasAuthorship W3216304313A5010481269 @default.
• W3216304313 hasAuthorship W3216304313A5012171078 @default.
• W3216304313 hasAuthorship W3216304313A5012408085 @default.
• W3216304313 hasAuthorship W3216304313A5013353605 @default.
• W3216304313 hasAuthorship W3216304313A5016086086 @default.
• W3216304313 hasAuthorship W3216304313A5016539643 @default.
• W3216304313 hasAuthorship W3216304313A5027511093 @default.
• W3216304313 hasAuthorship W3216304313A5029046324 @default.
• W3216304313 hasAuthorship W3216304313A5031625792 @default.
• W3216304313 hasAuthorship W3216304313A5032741097 @default.
• W3216304313 hasAuthorship W3216304313A5033285773 @default.
• W3216304313 hasAuthorship W3216304313A5034258667 @default.
• W3216304313 hasAuthorship W3216304313A5047423654 @default.
• W3216304313 hasAuthorship W3216304313A5050799087 @default.
• W3216304313 hasAuthorship W3216304313A5051049396 @default.
• W3216304313 hasAuthorship W3216304313A5053977995 @default.
• W3216304313 hasAuthorship W3216304313A5056280633 @default.
• W3216304313 hasAuthorship W3216304313A5061178911 @default.
• W3216304313 hasAuthorship W3216304313A5062829074 @default.
• W3216304313 hasAuthorship W3216304313A5062980285 @default.
• W3216304313 hasAuthorship W3216304313A5064342343 @default.
• W3216304313 hasAuthorship W3216304313A5065511569 @default.
• W3216304313 hasAuthorship W3216304313A5070756624 @default.
• W3216304313 hasAuthorship W3216304313A5072750068 @default.
• W3216304313 hasAuthorship W3216304313A5073439100 @default.
• W3216304313 hasAuthorship W3216304313A5077618800 @default.
• W3216304313 hasAuthorship W3216304313A5077916667 @default.
• W3216304313 hasAuthorship W3216304313A5079259624 @default.
• W3216304313 hasAuthorship W3216304313A5083553613 @default.
• W3216304313 hasConcept C126322002 @default.
• W3216304313 hasConcept C134018914 @default.
• W3216304313 hasConcept C170493617 @default.
• W3216304313 hasConcept C207001950 @default.
• W3216304313 hasConcept C2778163477 @default.
• W3216304313 hasConcept C2778824825 @default.
• W3216304313 hasConcept C2778849439 @default.
• W3216304313 hasConcept C2779120738 @default.
• W3216304313 hasConcept C2780072125 @default.
• W3216304313 hasConcept C2780948078 @default.
• W3216304313 hasConcept C43554185 @default.
• W3216304313 hasConcept C54355233 @default.
• W3216304313 hasConcept C71924100 @default.
• W3216304313 hasConcept C86803240 @default.
• W3216304313 hasConceptScore W3216304313C126322002 @default.
• W3216304313 hasConceptScore W3216304313C134018914 @default.
• W3216304313 hasConceptScore W3216304313C170493617 @default.
• W3216304313 hasConceptScore W3216304313C207001950 @default.
• W3216304313 hasConceptScore W3216304313C2778163477 @default.
• W3216304313 hasConceptScore W3216304313C2778824825 @default.
• W3216304313 hasConceptScore W3216304313C2778849439 @default.

• next